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Abstract
Background: Pulmonary cachexia is common in advanced chronic obstructive pulmonary disease (COPD), culminating in
exercise intolerance and a poor prognosis. Ghrelin is a novel growth hormone (GH)-releasing peptide with GH-independent
effects. The efficacy and safety of adding ghrelin to pulmonary rehabilitation (PR) in cachectic COPD patients were
investigated.
Methodology/Principal Findings: In a multicenter, randomized, double-blind, placebo-controlled trial, 33 cachectic COPD
patients were randomly assigned PR with intravenous ghrelin (2 mg/kg) or placebo twice daily for 3 weeks in hospital. The
primary outcomes were changes in 6-min walk distance (6-MWD) and the St. George Respiratory Questionnaire (SGRQ)
score. Secondary outcomes included changes in the Medical Research Council (MRC) scale, and respiratory muscle strength.
At pre-treatment, serum GH levels were increased from baseline levels by a single dose of ghrelin (mean change, +46.5 ng/
ml; between-group p,0.0001), the effect of which continued during the 3-week treatment. In the ghrelin group, the mean
change from pre-treatment in 6-MWD was improved at Week 3 (+40 m, within-group p=0.033) and was maintained at
Week 7 (+47 m, within-group p=0.017), although the difference between ghrelin and placebo was not significant. At Week
7, the mean changes in SGRQ symptoms (between-group p=0.026), in MRC (between-group p=0.030), and in maximal
expiratory pressure (MEP; between-group p=0.015) were better in the ghrelin group than in the placebo group.
Additionally, repeated-measures analysis of variance (ANOVA) indicated significant time course effects of ghrelin versus
placebo in SGRQ symptoms (p=0.049) and MEP (p=0.021). Ghrelin treatment was well tolerated.
Conclusions/Significance: In cachectic COPD patients, with the safety profile, ghrelin administration provided
improvements in symptoms and respiratory strength, despite the lack of a significant between-group difference in 6-MWD.
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Introduction
Pulmonary cachexia is common in the advanced stage of
chronic obstructive pulmonary disease (COPD), and it is an
independent risk factor for death in such patients [1,2]. Based on
the notion that advanced COPD affects the whole body and causes
wasting syndromes, many different therapeutic approaches have
been attempted to improve this syndrome [1,3].
Pulmonary rehabilitation (PR) including exercise training is well
accepted to improve exercise performance and quality of life in
COPD patients [4], and it has been regarded as a nutritional
adjunct therapy [5].
During the 1970s and 1980s, many gut peptides were identified
[6]. Ghrelin, first discovered in 1999 as a novel growth hormone
(GH)-releasing peptide isolated from the stomach, has been
identified as an endogenous ligand for GH secretagogue receptor
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e35708[7]. Ghrelin also has a variety of GH-independent effects, such as
causing a positive energy balance and weight gain by decreasing
fat utilization [8], stimulating food intake [9], and inhibiting
sympathetic nerve activity [10,11]. In addition, plasma ghrelin
levels were elevated in cachectic COPD patients and were
associated with the cachectic state and pulmonary function
abnormalities, suggesting that endogenous ghrelin increased to
compensate for the cachectic state and may provide important
clues to improve the catabolic-anabolic imbalance in such
patients[12]. In an open-label pilot study, we showed that ghrelin
treatment increased walking distance in cachectic COPD patients
[13]. Based on the above available evidence, a multicenter,
randomized, double-blind, placebo-controlled study was conduct-
ed to test the hypothesis that the addition of ghrelin treatment to
PR might benefit cachectic COPD patients. The objectives were
to investigate the efficacy and safety of adding ghrelin to PR in
cachectic COPD patients.
Methods
The protocol for this trial, supporting CONSORT checklist,
and Supplementary Methods are available as supporting infor-
mation; see Protocol S1, Checklist S1, and Supplementary
Methods S1.
Study Design and Patients
The study was a 3-week, multicenter, randomized, double-
blind, placebo-controlled trial of ghrelin administration during
PR. The study was finally conducted at four clinical centers
(National Cerebral and Cardiovascular Center, Miyazaki Univer-
sity School of Medicine, Nara Medical University, and National
Hospital Organization Toneyama National Hospital) in Japan
from September 2005 through May 2009, because Graduate
School of Medicine, Osaka City University did not participate just
before the start of the clinical trial. The study was conducted
according to the Declaration of Helsinki and Good Clinical
Practice guidelines and approved by the ethics committees of all
participating study centers: The ethics committee of the National
Cerebral and Cardiovascular Center (approval number, M17–13);
The ethics committee of Miyazaki University School of Medicine
(approval number, 218): The ethics committee of Nara Medical
University (approval number, 05–012); and The ethics committee
of the National Hospital Organization Toneyama National
Hospital (approval number, 0311). All patients gave written
Figure 1. Trial profile.
doi:10.1371/journal.pone.0035708.g001
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follows: 1) severe to very severe COPD (forced expiratory volume
in one second (FEV1)/forced vital capacity (FVC) of less than 70%
and FEV1 percent predicted of less than 50%); 2) underweight
(body mass index (BMI),21 kg/m
2); 3) clinically stable and able
to participate in PR; 4) between 20 and 85 years old; and 5) signed
the agreement for participation in this study. Participants were
excluded for any of the following: 1) malignant tumors; 2) active
infection; 3) severe heart disease; 4) hepatic dysfunction (serum
aspartate aminotransferase and alanine aminotransferase levels at
least twice the upper limit of normal); 5) renal dysfunction (serum
creatinine levels $2.0 mg/dl); 6) asthma; 7) definitely or possibly
pregnant; 8) change in drug regimen within 4 weeks before
participation in this study; or 9) judged to be unable to participate
in this study by their physician. This study was registered with
UMIN (University Hospital Medical Information Network in
Japan: http://www.umin.ac.jp/ctr/), number C000000061.
Randomization and Interventions
Randomization was done in each center considered as a block.
The randomization list was generated by a statistician from
Hamamatsu University School of Medicine and maintained there
until the study was finished and unblinded. Neither the physicians
nor the patients were aware of the treatment assignments. Patients
who met the eligibility criteria were enrolled and randomly
assigned in a 1:1 ratio to receive PR with either ghrelin (2 mg/kg)
or placebo twice a day for 3 weeks in hospital. The administration
of ghrelin (2 mg/kg, ghrelin solution with 10 ml saline) or placebo
was done intravenously over 30 minutes at a constant rate and
repeated twice a day for 3 weeks. Patients were tested at pre-
treatment, Week 3 after start of ghrelin or placebo administration
with PR, and Week 7 after start of ghrelin or placebo
administration with PR, i.e., 4 weeks after the completion of the
combination treatment (Figure 1).
Preparation of Human Ghrelin
Human ghrelin obtained from the Peptide Institute Inc. was
dissolved in distilled water with 3.75% D-mannitol and sterilized
as described previously [13]. Ghrelin was stored in 2-ml volumes,
each containing 120 mg ghrelin. The chemical nature and content
of the human ghrelin in vials were rarefied as described previously
[13]. All vials were stored frozen at 230uC until the time of
preparation for administration.
Table 1. Patients’ baseline characteristics. *
Ghrelin, n=14 Placebo, n=15 p value
Age, years
{ 70.5 (6.2), 63–80 73.9 (6.0), 63–82 0.15
Sex, male/female
{ 13/1 13/2 1.00
BMI, kg/m
2{ 18.6 (2.1), 14.4–20.9 18.0 (2.1), 14.7–20.9 0.38
Cigarette smoking, pack years
{ 62.0 (30.9), 3.8–125 52.5 (28.8), 0.0–97.5 0.38
Pulmonary function
{
FEV1, L 0.78 (0.20), 0.54–1.21 0.77 (0.21), 0.47–1.21 0.90
%FEV1, % predicted 31.6 (8.1), 21.2–49.5 34.5 (9.1), 17.7–45.9 0.32
FEV1/FVC, % 38.0 (8.9), 24.6–50.5 38.8 (8.7), 25.4–52.9 0.74
VC, L 2.48 (0.37), 1.90–3.45 2.52 (0.50), 1.62–3.69 0.98
%VC, % 78.8 (9.3), 64.0–94.3 84.5 (12.6), 71.4–113.4 0.38
Exercise capacity on ICPET
{
Peak _ V Vo2, ml/kg/min 11.5 (3.3), 5.2–17.5 11.3 (3.5), 6.2–18.7 0.74
6-MWD, m
{ 328 (110), 148–619 315 (118), 85–498 0.84
SGRQ
{
Total score 58.2 (16.5), 36.3–84.4 50.2 (15.5), 21.3–77.3 0.23
Symptoms score 61.5 (22.5), 29.4–97.5 51.6 (19.8), 19.7–78.5 0.34
Activity score 72.5 (14.9), 41.7–92.5 65.9 (16.3), 35.3–92.5 0.34
Impacts score 46.7 (19.5), 20.0–84.4 39.2 (17.7), 9.4–69.7 0.53
Medications
{
LAMA 9 6 0.27
SAMA 3 2 0.65
LABA 9 7 0.46
SABA 2 0 0.22
ICS 5 2 0.21
Methylxanthines 7 7 1.00
Data are presented as means (SD), and the minimum and maximum values unless otherwise stated. BMI=body mass index; FEV1=forced expiratory volume in one
second; FVC=forced vital capacity; ICPET=incremental cardiopulmonary exercise testing; ICS=inhaled corticosteroids; LABA=long-acting b2-agonist; LAMA=long-
acting muscarinic antagonist; SABA=short-acting b2-agonist; SAMA=short-acting muscarinic antagonist; VC=vital capacity.
*The groups shown represent only patients analyzed for efficacy. Medications are not mutually exclusive, and data are presented separately.
{Analyzed using a Wilcoxon rank sum test.
{Analyzed using a Fisher’s exact test.
doi:10.1371/journal.pone.0035708.t001
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Exercise training, which was included in the PR program, was
conducted in three sets daily, every weekday for 3 weeks (i.e.
15 days) at high-intensity targets. Additional details are described
online in Supplementary Methods S1.
Outcome Measure
Efficacy: The primary outcomes were changes in 6-min walk
distance (6-MWD) and the score evaluated using the St. George
Respiratory Questionnaire (SGRQ) [14]. Secondary outcomes
were changes in the health-related QoL (HRQoL) score using the
Short-Form 36 questionnaire (SF 36 v2
TM Health Survey,
Japanese version) [15,16,17] and the Medical Research Council
(MRC) dyspnea scale [18], peak oxygen uptake ( _ V Vo2), food intake,
FEV1/FVC, vital capacity (VC), respiratory muscle strength, and
plasma norepinephrine levels in the resting condition.
Safety: All randomized patients who received at least one dose
of the study treatments (ghrelin group, n=18; placebo group,
n=15) were included in the safety analyses using intention-to-treat
analysis. Blood tests were done up to Week 7. All serious adverse
events were monitored throughout the study period.
6-min Walk Test
The 6-MWD was measured as described previously [13].
Cardiopulmonary Exercise Testing (CPET)
While breathing room air with a mask, symptom-limited CPET
was conducted on an electrically braked cycle ergometer using an
incremental protocol (continuous ramp rate of 5 W/min). Expired
gas data were measured breath-by-breath and collected as 30-s
averages at rest and during exercise. The CPET was done until
subject exhaustion.
Food Intake
Food intake was assessed as described previously [13].
Respiratory and Peripheral Muscle Strength
The maximal inspiratory pressure (MIP) and maximal expira-
tory pressure (MEP) were measured as described previously [13].
Peripheral muscle strength was measured by the maximal
voluntary handgrip maneuver as described previously [13].
Figure 2. Change from pre-treatment in 6-min walk distance (6-MWD), Medical Research Council (MRC) score, and maximal
expiratory pressure (MEP) over time. Open circles, ghrelin; closed circles, placebo. Data are presented as mean differences6SE. * p,0.05:
change between pre- and post-treatment (within-group difference).
{ p,0.05: change between pre-treatment and post-treatment (between ghrelin
and placebo group difference).
{ p,0.05: time course effect of ghrelin versus placebo by repeated-measures ANOVA. A) In both groups, 6-MWD
increases significantly to a similar level from pre-treatment at Week 3. Prolonged effects can be seen in the ghrelin group at Week 7, though the
improvement in 6-MWD declined in the placebo group. B) Though the MRC score became progressively worse in the placebo group, the maintained
effects in the MRC score can be seen in the ghrelin group at Week 7. C) Repeated-measures ANOVA indicated significant time course effects of ghrelin
versus placebo in MEP (F (2, 51)=4.17, p=0.021).
doi:10.1371/journal.pone.0035708.g002
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All participating centers measured dual energy x-ray absorpti-
ometry (DEXA) to assess the total body composition, including
lean body mass. The measurements were performed with the
subject lying in a supine position. As a general rule, a single expert
from each center analyzed the scans from the corresponding
center.
Blood Samples and Analyses
Serum GH, serum insulin-like growth factor (IGF)-1, serum
tumor necrosis factor a (TNF-a), serum interleukin-6 (IL-6), and
plasma norepinephrine were measured as described previously
[13]. Additional details are described online in Supplementary
Methods S1.
Sample Size
The study’s target accrual was 60 in the original protocol at the
time of study design (see supporting information; Protocol S1).
When 31 of the 33 randomized patients completed this study, we
re-performed the power and sample size calculation, and
confirmed that the number of patients that had completed the
study exceeded the number necessary for the re-calculated sample
size of 18. As a result, this trial ended prematurely. Because i) it is
difficult to prolong hospitalization considering the current status of
health care insurance in Japan, and ii) what constituted a clinically
important change in 6-MWD after ghrelin treatment with PR was
not known before the study ended; the sample size calculation was
re-performed on the estimated effect of only ghrelin treatment for
improving 6-MWD, which was based on information from the
pilot study [13]. The resultant total sample size of 18 was finally
used to provide the power (80%) to detect a mean difference of
60 m in 6-MWD with an estimated SD of 40 m using a two-sided
alpha of 0.05, though the study’s target accrual stated in the
original protocol was 60.
Statistical Analysis
All data are expressed as means6SD or SE unless otherwise
indicated. Comparisons of baseline characteristics between the two
groups were made by Fisher’s exact tests and Wilcoxon rank sum
tests. Effects were examined once or twice; that is i) at Week 3 soon
after 3-week treatment or ii) at Week 3 and Week 7 (i.e., 4 weeks
after the completion of 3-week treatment). The results at Week 3
and Week 7, respectively, were compared with the pre-treatment
within each group, and between the two groups using paired t-tests
and unpaired t-tests, respectively. To assess the time course
efficacy of ghrelin versus placebo, post-treatment data up to Week
7 were also assessed using a repeated-measures analysis of variance
Table 2. Changes in pre-treatment exercise capacity, pulmonary function and other parameters during pulmonary rehabilitation
with ghrelin or placebo.
At Week 3 At Week 7
Ghrelin,
n=14
Placebo,
n=15
Treatment effect
(95% CI; p value)
Ghrelin,
n=14
Placebo,
n=13
Treatment effect
(95% CI; p value)
Exercise capacity
6-MWD, m 40 (17)
* 35 (12)
* 5( 237 to 48; 0.81) 47 (17)
* 18 (11) 29 (215 to 73; 0.19)
Peak _ V Vo2,
ml/min/kg
1.2 (0.4)
* 0.5 (0.3) 0.7 (20.4 to 1.8; 0.21) ND ND ND
Peak _ V Vo2/HR,
ml/beats
0.5 (0.2)
* 20.4 (0.5) 0.9 (20.2 to 2.0; 0.11) ND ND ND
PFT
FEV1/FVC, % 21.1 (1.0) 22.7 (0.9)
* 1.6 (21.2 to 4.3; 0.26) 21.7 (1.2) 21.2 (1.1) 20.5 (23.8 to 2.8; 0.77)
VC, L 0.14 (0.07) 0.11 (0.07) 0.03 (20.16 to 0.23; 0.74) 0.09 (0.11) 20.10 (0.07) 0.19 (20.09 to 0.47; 0.17)
Others
MIP, cmH20 28.2 (4.9) 29.8 (3.2)
** 1.6 (210.1 to 13.4; 0.78) 28.4 (5.6) 24.3 (2.6) 24.1 (217.7 to 9.5; 0.52)
MEP, cmH20 6.8 (4.4) 23.8 (4.5) 10.7 (22.2 to 23.5; 0.099) 15.6 (5.7)
* 24.3 (4.8) 19.9 (4.1 to 35.6; 0.015)
Food intake,
kcal/day
122 (93) 217 (86) 139 (2122 to 399; 0.28) ND ND ND
MRC, score 20.2 (0.2) 0.3 (0.3) 20.4 (21.2 to 0.3; 0.22) 20.2 (0.2) 0.6 (0.3) 20.7 (21.4 to 20.1; 0.030)
Plasma NE, ng/ml 20.063 (0.061) 20.066 (0.067) 0.004 (20.183 to 0.190; 0.97) ND ND ND
IL-6 NE, pg/ml 1.52 (1.33) 0.08 (0.21) 1.44 (21.35 to 4.22; 0.31) ND ND ND
TNF-a, pg/ml 0.29 (0.15) 0.08 (0.06) 0.21 (20.12 to 0.54; 0.21) ND ND ND
Mean BP, mmHg 213 (3)
** 23 (4) 210 (220 to 1; 0.061) 22 (3) 4 (4) 26( 217 to 4; 0.20)
Body weight, kg 0.1 (0.3) 0.4 (0.3) 20.3 (21.2 to 0.7; 0.58) 0.8 (0.4) 0.4 (0.4) 0.4 (20.7 to 1.4; 0.49)
Total lean mass, kg 0.2 (0.5) 0.5 (0.3) 20.2 (21.5 to 1.1; 0.73) ND ND ND
Grip strength, kg 0.3 (0.9) 20.0 (0.5) 0.3 (21.7 to 2.3; 0.76) 1.1 (0.9) 2.5 (1.1)
* 21.5 (24.4 to 1.4; 0.31)
Data are means (SE), or mean effect (95% CI; p value) unless otherwise indicated. BP=blood pressure; FEV1=forced expiratory volume in one second; FVC=forced vital
capacity; IL=interleukin; MEP=maximal expiratory pressure; MIP=maximal inspiratory pressure; MRC=medical research council; ND=not done; NE=norepinephrine;
PFT=pulmonary function test; VC=vital capacity.
*p,0.05,
**p,0.01: change between pre-treatment and post-treatment within-group difference.
doi:10.1371/journal.pone.0035708.t002
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SAS Institute Inc., Cary, NC, USA).
Results
Of the 33 randomized patients, 31completed the 3-week study;
2 patients in the ghrelin group discontinued study medications due
to pneumonia and depression, respectively. Of the 31 patients who
completed the randomized 3-week study, in the ghrelin group, one
patient had infective enteritis after 3 weeks of medications, and
one had low back pain due to lumbar spondylosis before and
throughout the 3 weeks of medications. Two patients in the
placebo group were lost to follow-up after the Week 3
measurements. Therefore, 29 patients (ghrelin, n=14; placebo,
n=15) were included in the study analyses to ensure adequate
efficacy evaluation using pre-protocol analysis. The mean BMI in
the enrolled patients (n=29) was very low (mean6SD,
18.362.1 kg/m
2). The treatment groups were generally well-
matched with regard to demographics and baseline characteristics
(Table 1).
Somatotropic Function
At pre-treatment, compared with placebo, a single administra-
tion of ghrelin markedly increased serum GH levels from baseline
(mean change6SE: ghrelin group 46.466.2 ng/ml at the mean
peak time (35 min) versus the placebo group 1.160.5 ng/ml at the
mean peak time (55 min); between group p,0.0001), the effect of
which was maintained at Week 3 (mean change6SE: ghrelin
group 15.862.1 ng/ml at the mean peak time (30 min) versus the
placebo group 0.460.2 ng/ml at the mean peak time (65 min);
between group p,0.0001). Three-week ghrelin-PR combination
treatment tended to increase serum IGF-1 levels (mean chang-
e6SE: 1266 ng/ml, within-group p=0.093).
Exercise Tolerance and Gas Exchange Measurements
At both Week 3 and Week 7, there were no significant
differences between the ghrelin and placebo groups in 6-MWD. In
each group, at Week 3, a similar significant increase from pre-
treatment in 6-MWD was observed (mean difference: ghrelin
group +40 m, within group p=0.033 versus placebo group
+35 m, within group p=0.013). The effect remained at Week 7
in the ghrelin group, whereas in the placebo group, the
Figure 3. Change from pre-treatment in St. George Respiratory Questionnaire (SGRQ) scores over time. Open circles, ghrelin; closed
circles, placebo. Data are presented as mean differences6SE. * p,0.05: change between pre- and post-treatment (within-group difference).
{ p,0.05:
change between pre-treatment and post-treatment (between ghrelin and placebo group difference).
{ p,0.05: time course effect of ghrelin versus
placebo by repeated-measures ANOVA. At Week 3, marked improvements in SGRQ scores are not seen in both groups. However, SGRQ scores,
especially SGRQ symptom scores, are significantly improved in the ghrelin group at Week 7. B) Repeated-measures ANOVA indicated significant time
course effects of ghrelin versus placebo in SGRQ symptoms (F (2, 51)=3.19, p=0.049).
doi:10.1371/journal.pone.0035708.g003
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ghrelin group within group +47 m, p=0.017 versus placebo group
+18 m, within group p=0.14) (Table 2 and Figure 2A). To assess
the time course efficacy of ghrelin versus placebo in 6-MWD, a
repeated-measures ANOVA was performed. There was no
significant time course effect of ghrelin versus placebo in 6-
MWD (F (2, 51)=1.10, p=0.34).
In the ghrelin group, the peak _ V Vo2 and _ V Vo2/HR were
significantly increased by 1.2 ml/kg/min and 0.5 ml/beats,
respectively, from pre-treatment (within-group p=0.021,
p=0.019, respectively) (Table 2). However, there was no
significant difference between the two groups in the peak _ V Vo2
and _ V Vo2/HR. In the ghrelin group, the ventilatory equivalents for
oxygen ( _ V VE/ _ V Vo2) was relatively improved by 23.9 from pre-
treatment (within group p=0.060).
HRQoL and MRC Measures
In both groups, there was no significant difference in each
SGRQ score and MRC score between pre-treatment and at
Week 3. At Week 7, there was a significant treatment effect
between the two groups in SGRQ symptoms (between-group:
p=0.026, Table 3 and Figure 3B), and in the MRC score
(between-group p=0.030, Table 2 and Figure 2B). At Week 7, in
the ghrelin group, SGRQ total was decreased by 6.0 from pre-
treatment (within-group p=0.046, between-group p=0.072)
(Table 3 and Figure 3A). Furthermore, there was a significant
time course effect of ghrelin versus placebo in SGRQ symptoms
(repeated-measures ANOVA, F (2, 51)=3.19, p=0.049,
Figure 3B).
Body Weight and Food Intake
I nt h eg h r e l i ng r o u p ,a tW e e k1 ,t h er e l a t i v ei n c r e a s ei nb o d y
weight was+0.42 kg (within group p=0.092), which was
r e d u c e db yW e e k3a n df o l l o w e db yar e - i n c r e a s ea tW e e k7
(+0.8 kg, within group: p=0.054). However there was no
significant difference in body weight between the groups at each
Week (Table 2). No affect on whole lean body mass from ghrelin
was seen at Week 3 (Table 2). No significant increase from
baseline in food intake was observed at Week 3 in both groups
(Table 2).
Table 3. Changes in pre-treatment scores of health-related quality of life during pulmonary rehabilitation with ghrelin or placebo
At Week 3 At Week 7
Ghrelin,
n=14
Placebo,
n=15
Treatment effect
(95% CI; p value)
Ghrelin,
n=14
Placebo,
n=13
Treatment effect
(95% CI; p value)
SGRQ
Total 25.0 (3.2) 23.9 (3.5) 21.1 (210.9 to 8.7; 0.83) 26.0 (2.7)
* 0.8 (2.4) 26.8 (214.4 to 0.7; 0.072)
Symptoms 21.7 (3.0) 0.3 (5.9) 21.9 (216.2 to 12.3; 0.77) 29.4 (4.0)
* 6.4 (5.4) 215.8 (229.5 to 22.1; 0.026)
Activity 24.5 (3.5) 25.0 (3.9) 0.4 (210.5 to 11.4; 0.94) 0.1 (2.2) 1.3 (2.7) 21.2 (28.3 to 5.9; 0.73)
Impacts 26.3 (4.1) 24.1 (3.1) 22.2 (212.6 to 8.2; 0.67) 28.9 (3.7)
* 21.9 (3.0) 27.0 (216.9 to 2.9; 0.16)
SF-36
Physical
functioning
4.6 (6.1) 0.3 (3.9) 4.3 (210.0 to 18.5; 0.55) 3.1 (4.7) 26.9 (4.9) 10.0 (23.9 to 23.9; 0.15)
Role physical 28.3 (6.9) 24.6 (5.4) 23.7 (221.6 to 14.1; 0.67) 212.0 (4.1)
* 222.6 (7.3)
** 10.6 (26.8 to 27.9; 0.22)
Bodily pain 26.8 (5.3) 8.4 (6.4) 215.2 (233.0 to 2.6; 0.090) 27.6 (6.5) 23.8 (6.8) 23.8 (223.2 to 15.7; 0.69)
General health 20.6 (4.5) 2.9 (5.2) 23.5 (217.9 to 11.0; 0.63) 0.5 (3.4) 5.8 (5.4) 25.3 (218.5 to 7.9; 0.41)
Vitality 5.7 (5.5) 7.8 (4.4) 22.0 (216.3 to 12.3; 0.77) 3.4 (4.8) 22.9 (3.4) 6.2 (25.9 to 18.4; 0.30)
Social functioning 23.1 (9.5) 3.3 (7.2) 26.5 (230.5 to 17.6; 0.59) 212.5 (8.1) 22.9 (6.0) 29.6 (230.5 to 11.3; 0.35)
Role emotional 213.9 (5.2)
* 29.5 (9.2) 24.4 (227.7 to 18.8; 0.68) 219.9 (6.6)
* 216.0 (10.4) 23.9 (229.3 to 21.5; 0.76)
Mental health 0.4 (6.0) 3.7 (4.2) 23.3 (218.0 to 11.5; 0.65) 3.5 (3.3) 28.2 (4.6) 11.7 (0.0 to 23.4; 0.050)
Data are means (SE), or mean effect (95% CI; p value) unless otherwise indicated. SGRQ=St. George Respiratory Questionnaire; SF 36=short-Form 36.
*p,0.05,
**p,0.01: change between pre-treatment and post-treatment within-group difference.
doi:10.1371/journal.pone.0035708.t003
Table 4. Adverse events.
Event
Ghrelin,
n=18
Placebo,
n=15
Patients with at least 1 adverse event 12 (67) 5 (33)
Adverse events not considered study therapy-related
Pneumonia 1 (6) 0 (0)
Depression 1 (6) 0 (0)
Infective enteritis 1 (6) 0 (0)
Lung cancer* 1 (6) 0 (0)
Hypercalcemia 0 (0) 1 (7)
Adverse events considered study therapy-related
Stomach rumbling 3 (17) 2 (13)
Feeling of being warm 4 (22) 0 (0)
Feeling of hunger 2 (11) 2 (13)
Thirst 2 (11) 0 (0)
Slight liver dysfunction 1 (6) 0 (0)
Hypercholesterolemia 1 (6) 0 (0)
Hypoproteinemia 1 (6) 2 (13)
Values are presented as n (% of group). * One patient developed lung cancer 2
years and 9 months after study treatment.
doi:10.1371/journal.pone.0035708.t004
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In the ghrelin group, at Week 3, the post-treatment increase in
respiratory muscle strength, as indicated by MEP and MIP, was
not significantly different from that in the placebo group, but at
Week 7, the mean increase from pre-treatment in MEP (+15.6
cmH2O) was significantly different from that in the placebo group
(between group p=0.015) (Table 2). Furthermore, there was a
significant time course effect of ghrelin versus placebo in MEP
(repeated-measures ANOVA, F (2, 51)=4.17, p=0.021,
Figure 2C).
At Week 3 and Week 7, there was no significant treatment effect
between the two groups in grip strength (Table 2).
Pulmonary Function, Plasma Norepinephrine, and Other
Hormone Levels
Ghrelin treatment did not significantly change any parameters
of the pulmonary function tests, serum TNF-a, serum IL-6, or
plasma norepinephrine at rest (Table 2).
Safety
Throughout this trial, 67% of patients in the ghrelin group and
33% of patients in the placebo group reported 12 and 5 adverse
events, respectively, but there was no significant difference
between the groups (Table 4). In the ghrelin group, alanine
aminotransferase increased to 41 IU/L in one patient (6%), and
total cholesterol increased to 270 mg/dl in one patient (6%); both
increases disappeared at Week 7. Two patients randomized to
ghrelin discontinued as a result of adverse events: one because of
bacterial pneumonia, and one because of depression, both of
which were not considered related to ghrelin treatment. One
patient randomized to ghrelin developed lung cancer 2 years and
9 months after the end of ghrelin administration, but this was
judged by the efficacy and safety committee as not causally related
to ghrelin treatment, considering the period of disease develop-
ment and the incidence rate of lung cancer [19].
Discussion
The present study is the first multicenter, randomized, double-
blind, placebo-controlled study to assess the effect and safety of
repeated ghrelin administration to very severe cachectic patients
with COPD. The main results of this study can be summarized as
follows. In the ghrelin group, single administration of ghrelin was
accompanied by a significant increase in serum GH levels during
3-week treatment, and there was no significant difference in 6-
MWD between ghrelin and placebo at Week 3 and at Week 7.
With ghrelin, symptomatic improvements in SGRQ symptoms
and MRC score were not obtained at Week 3, but significant
differences between ghrelin and placebo were seen at Week 7. In
the ghrelin group, no significant within-group improvement from
pre-treatment was seen in respiratory muscle strength, as indicated
by MEP and MIP, at Week 3, but there was a significant difference
in MEP between ghrelin and placebo at Week 7. Repeated-
measures ANOVA showed significant time course effects of
ghrelin versus placebo in SGRQ symptoms and MEP. Finally,
ghrelin treatment was well tolerated.
Ghrelin treatment may have beneficial, continuing effects after
treatment on HRQoL and MRC measures in this population.
Though this study was conducted to determine the effectiveness of
ghrelin in cachectic COPD patients, considering a synergistic
interaction between ghrelin and PR, the data of this study need to
be interpreted with caution, because, especially in advanced stage
patients, excessive exercise training may partially worsen the
anabolic and catabolic balance [1,20]. In the present study, which
included patients with a lower exercise capacity and pulmonary
function than those in the pilot study [13] and more cachectic
patients than those in other studies on PR [21], the 6-MWD after
3-week PR in the placebo group was decreased in 3 (20%) of the
15 patients. Since 5 patients (33%) in the placebo group found the
initial training work rate intolerable, the initial training work rate
remained at its initial setting. In addition, at Week 3, outcome
measurements showed no improvements with ghrelin compared
with placebo. These findings may represent patients’ variable
responses to PR, which might have an influence on the effects of
ghrelin. Of note, however, there were significant treatment effects
of ghrelin in both SGRQ symptoms and MRC score. In addition,
the treatment tended to improve the total SGRQ score by more
than 4 points; a clinically meaningful improvement. These effects
were not observed soon after the 3 week-treatment, but were seen
4 weeks after treatment, maintaining the improvement obtained in
6-MWD at Week 3. Similarly, 4 weeks after treatment, the effect
of ghrelin on respiratory muscle strength was confirmed, though it
has been reported that GH alone does not increase strength in
healthy elderly [22,23,24]. Furthermore, repeated-measures AN-
OVA indicated significant time course effects of ghrelin versus
placebo in SGRQ symptoms and MEP. Our data suggest that
improving of the respiratory muscle strength, the O2 pulse, and the
ventilatory equivalents for oxygen may serve as a mechanism by
which ghrelin-PR combination treatment improved symptoms,
though further examination is needed to understand the precise
mechanism. These findings suggest that repeated ghrelin admin-
istration may have beneficial, sustained effects after administration
on symptoms through GH-dependent and/or -independent
mechanisms.
Cachectic elderly patients with COPD who were given
intravenous ghrelin showed a continuous increase of pulsatile
GH secretion in the present study. There is evidence that
insufficiency of sarcopenia-related hormones, such as GH and
IGF-1, may contribute to cachexia [25,26]. Observational studies
in cachectic COPD patients have found decreased levels of these
hormones [27,28]. In the present study, despite significant
increases in GH secretion levels throughout the 3-week treatment
and respiratory muscle strength, ghrelin provided only a significant
within-group increase in exercise performance, and a relative
within-group increase in IGF-1 levels and body weight. Further-
more, ghrelin did not affect food intake, grip strength or plasma
norepinephrine levels at rest in the present study. Although DEXA
should be performed a greater number of times during the trial, at
Week 3 ghrelin did not show any effects on whole lean body mass.
Meanwhile, previous studies showed that ghrelin administration
induced a positive energy balance and weight gain [8], increased
food intake [9,13], and decreased sympathetic nervous activity
[10,11,13]. The discrepancy may be explained by the fact that the
intensity of exercise training for some cachectic participants
counteracted the effects of ghrelin, though lower extremity
exercise training at higher intensity produces greater benefits than
lower intensity training [4]. As one of the reasons, the patients
treated with both ghrelin and exercise training gained at Week 1,
which was not seen in the placebo group. However, this weight
gain reduced by Week 3. At Week 7, the weight was regained
(Table 2). The days of attending PR in the ghrelin group was
negatively correlated with the increase in body weight from Week
3 to Week 7 (r=20.710, p=0.003). We speculate that the
unintended excessive exercise permitted by ghrelin administration
with antidepressant-like effects [29] might prevent the obtained
results. Nevertheless, these findings suggest that clinical interven-
tions with ghrelin may help cachectic COPD patients via
inhibiting somatopause and regulating metabolic balance.
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e35708The participants in the present study tolerated daily adminis-
tration of ghrelin for 3 weeks (Table 4); the most frequent ghrelin-
related side effects were mild and similar to those of previous
reports [13,30,31], as well as with those of GH administration by
injection [22]. However, given that the previous studies of the
responses of ghrelin in proliferation, including tumor develop-
ment, have demonstrated conflicting findings [32,33,34,35], more
studies of the safety of ghrelin treatment are necessary before
clinical application.
This study had some limitations. First, the number of
participants was small, and few females were included in this
trial. Second, the duration of the study was short. A more effective
exercise training program, considering its intensity and frequen-
cies, should have been conducted. Additional studies are needed to
evaluate a more suitable regimen of ghrelin-PR.
In conclusion, ghrelin administration provided sustained
improvements in symptoms and respiratory strength in cachectic
COPD patients. Development of ghrelin administration methods
may offer potential advantages over the currently approved
treatment options for COPD. The lack of a significant between-
group difference in exercise tolerance may result from the exercise
training program conducted as the combination therapy. Careful
examination is needed to develop more effective administration
methods of ghrelin and combination therapy with ghrelin.
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